Can Hong Kong lure biotech without inflating a bubble? – STAT

STAT
AMBRIDGE, Mass. — Two Chinese drug makers have already taken advantage of new rules that ease the way for pre-revenue biotechs to raise capital on Hong Kong’s stock exchange: hepatology-focused drug developer Ascletis applied to list there 1 last …
Hong Kong Gay Rights Suffer SetbacksVoice of America

all 6 news articles

…read more

Source:: Hong Kong News By Google News

Leave a Comment